Refractory relapsing polychondritis treated with serial success with interleukin 6 receptor blockade

Journal of Rheumatology

Volumn 40, Issue 1, 2013, Pages 100-101

  Wallace, Zachary S ^a   Stone, John H ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; INFLIXIMAB; INTERLEUKIN 6 RECEPTOR; PREDNISONE; TOCILIZUMAB;

AGED; BRONCHITIS; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EAR DISEASE; EAR ERYTHEMA; EAR SWELLING; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LETTER; NASAL BRIDGE SWELING; NOSE DISEASE; OTALGIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEPTOR BLOCKING; RECURRENT DISEASE; RELAPSING POLYCHONDRITIS; THORAX PAIN; THROMBOCYTOSIS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CYCLOPHOSPHAMIDE; FEMALE; GLUCOCORTICOIDS; HUMANS; POLYCHONDRITIS, RELAPSING; RECEPTORS, INTERLEUKIN-6; RETREATMENT; TREATMENT OUTCOME;

EID: 84871880722     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120381     Document Type: Letter

References (7)

1. Lahmer T, Treiber M, von Werder A, Foerger F, Knopf A, Heemann U, et al. Relapsing polychondritis: An autoimmune disease with many faces. Autoimmun Rev 2010;9:540-6.
2. de Barros AP, Nakamura NA, Santana T de F, Motta JQ, Bianchi WA. Infliximab in relapsing polychondritis. Rev Bras Reumatol 2010;50:211-6.
3. Edrees A. Relapsing polychondritis: A description of a case and review article. Rheumatol Int 2011;31:707-13.
4. Campbell L, Chen C, Bhagat SS, Parker RA, Ostor AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: A systematic literature review and meta-analysis of randomized controlled trials. Rheumatology 2011;50:552-62.
5. Murakami M, Nishimoto N. The value of blocking IL-6 outside of rheumatoid arthritis: Current perspective. Curr Opin Rheumatol 2011;23:273-7.
6. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008;112:3959-64.
7. Kawai M, Hagihara K, Hirano T, Shima Y, Kuwahara Y, Armitisu J, et al. Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis. Rheumatology 2009;48:318-9.